Efficacy and Safety of Acupuncture for the Hot Flashes in Breast Cancer Patients Taking Adjuvant Tamoxifen : A Multicenter Study in Korean Women

Size: px
Start display at page:

Download "Efficacy and Safety of Acupuncture for the Hot Flashes in Breast Cancer Patients Taking Adjuvant Tamoxifen : A Multicenter Study in Korean Women"

Transcription

1 Efficacy and Safety of Acupuncture for the Hot Flashes in Breast Cancer Patients Taking Adjuvant Tamoxifen : A Multicenter Study in Korean Women Daegu Catholic University Medical Center Department of Endocrine & Breast Sugery Herion Choi

2 Introduction Breast cancer 2 nd most common cancer in Korean women

3 Introduction Adjuvant antiestrogen therapy - Tamoxifen Hot flashes Contraindication of HRT Non-hormonal modalities for hot flashes Clonidine, SSRI, SNRI, gabapentin Complementary medicines - Acupuncture

4 Introduction THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 19, Number 8, 2013, pp

5 Introduction Prospective, single-arm, observational study 10 Korean women with breast cancer Effective relief from hot flashes Effects lasted for at least 1 month after termination of treatment

6 Purpose To evaluate the efficacy and safety of acupuncture for treatment of hot flashes in Korean women breast cancer patients taking tamoxifen as adjuvant endocrine therapy Randomized Controlled Multicenter Interventional Study

7 Patients & Method Study Period ㅣ March 2017 September 2017 Recruitment ㅣ April 2017 June 2017 Data Collection ㅣ April 2017 July Korean women breast cancer patients taking tamoxifen and reported moderate to severe hot flashes Acupuncture group(n=15) Control group(n=15)

8 Patients & Method Primary end point Peak Hot Flash 100mm VAS (Visual analogue scale) Hot Flash Score (Frequency * grade) Secondary end point EORTC QLQ C-30 QLQ BR-23

9 Patients & Method Inclusion Criteria Pre- or postmenopausal status Moderate or severe vasomotor symptoms 3 or more hot flashes / wk Karnofsky performance score of > 60 Voluntary participation Cessation of HRT or other pharmacologic or alternative treatments for hot flashes at least 4 weeks before the trial Exclusion Criteria Pharmacologic or other alternative treatment for hot flashes during the trial Serious medical or psychiatric conditions Hot flashes caused by menopause

10 Patients & Method Intervention 4 wks of treatment with 3 acupuncture sessions/wk 20 ± 5 minutes duration Performed by a traditional Korean medicine (TKM) physician 10-20mm depth 5 points using 8 disposable stainless steel needles (GV 20, M-HN-3, HT 8, KI 10, LV 2)

11 Wk Visit Sc Sc AC V/S VAS/ HFS EORTC AE Comp Sc : Screening, AC : Acupuncture, V/S : Vital Sign, HFS : Hot flash score AE : Adverse event, Comp : Compliance

12 Baseline characteristics Results Variable Group N(%) or mean±sd Acupuncture group Control group P-value Age (years) 48.73± ± Weight (Kg) 62.75± ± Height (cm) 160.6± ± Invasive cancer 14(93.3) 12(80) Duration of tamoxifen(months) 35.27± ± Premenopause 15(100) 14(93.3) 1.000

13 Effects of Acupuncture on Vital Sign Ac Ct Ac Ct DBP SBP Results Visit Visit No Statistically significant vital sign change during the treatment period in both Acupuncture group and Control group Ac Ct AC Ct BT PR Visit Visit

14 Results Effects of Acupuncture on Hot Flash VAS & Hot Flash Score Time, mean(sd) p-value Variable Group V1 1) V4 2) V7 3) V10 4) V13 5) V14 6) T G T*G * Acupuncture.000* Hot flash (18.46) (11.93) (14) (14.6) (13.56) (13.45) 1 1>2,3,4.000* VAS ,3,4,5, Control,5,6 (12.65) (14.24) (15.52) (18.21) (17.92) (22.95) * Acupuncture Hot Flash (4.29) (4.21) (4.34) (3.27) (1.91) (2.88) Score ,3,4,5, Control (5.66) (14.25) (23.04) (20.22) (30.88) (25.72) 6 * : Statistically significant with p<0.05 : Multiple comparison result by contrast

15 Results VAS Ac Ct HFS AC Ct Visit Visit Severity of hot flashes was significantly reduced in Acupuncture group during the treatment period The reduction in symptoms was maintained until week 8

16 Effects of Acupuncture on EORTC QoL Questionnaire Results Variable EQC30 Global Health status EQC30 Functional scale EQC30 Symptom scale EQBR23 Functional scale EQBR23 Symptom scale Time, mean(sd) p-value Group V1 1) V13 2) V14 3) T G T*G Acupuncture 49.44(21.01) 65.01(22.09) 69.99(16.3) Control 59.45(19.64) 58.89(16.52) 53.33(19.6) Acupuncture 71.25(15.05) 80.22(7.3) 81.26(11.98).009* Control 76.23(9.76) 76.43(11.02) 77.19(9.75) Acupuncture 29.51(16.32) 21.41(10.78) 18.65(10.62).001* Control 24.99(9.23) 22.17(12.35) 20.77(10.95) Acupuncture 41.11(17.18) 42.16(14.23) 47.33(16.04).036* Control 31.71(14.92) 31.99(16.47) 34.89(15.22) Acupuncture 33.79(17.29) 22.85(11.79) 22.55(12.96).001* Control 28.31(12.96) 23.28(12.46) 24.07(10.11) 1<2, * 1 2,3.027* 1 2,3 1>2> <2< >2, * : Statistically significant with p<0.05 : Multiple comparison result by contrast

17 Results EORTC QLQ C-30 Global Health Ac Ct EORTC QLQ C-30 Functional Scale AC Ct Visit Visit QoL of Acupuncture group is improved during the treatment period The improvement of QoL was lasted for 1month after the Tx cessation

18 Safety Results Group (N, (%)) Variable p-value Acupuncture Control AE 0(0) 0(0) N/A SAE 9(0) 0(0) N/A Medical Hx Exist 4(26.7) 3(20.0) None 11(73.3) 12(80.0) * : Statistically significant with p<0.05 AE: Adverse Event, SAE : Serious Adverse Event Acupuncture was safe in patients with underlying disease

19 Conclusions Acupuncture can be a useful and safe alternative treatment for alleviation of facial flashes in patients with breast cancer who are undergoing antiestrogen therapy The effects lasted for at least 1 month after termination of treatment Small sample size Limitations Short follow-up period Lack of the method to rule out placebo effect

20 Thank you for your attention

This includes bone loss, endometrial cancer, and vasomotor symptoms.

This includes bone loss, endometrial cancer, and vasomotor symptoms. Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to

More information

Managing menopause in Primary Care and recent advances in HRT

Managing menopause in Primary Care and recent advances in HRT Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims

More information

Managing menopause in Primary Care and recent advances in HRT

Managing menopause in Primary Care and recent advances in HRT Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway

More information

Management of Menopausal Symptoms in Patients with Breast Cancer. Mike Dixon Edinburgh Breast Unit

Management of Menopausal Symptoms in Patients with Breast Cancer. Mike Dixon Edinburgh Breast Unit Management of Menopausal Symptoms in Patients with Breast Cancer Mike Dixon Edinburgh Breast Unit Menopausal symptoms have a major impact on Quality of Life Variety of Symptoms associated with the Menopause

More information

Issues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010

Issues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010 Issues in Cancer Survivorship Larissa A. Korde, MD, MPH June 26, 2010 Estimated US Cancer Cases in Women: 2006-2008 CA Cancer J Clin 2006; 56:106-130; CA Cancer J Clin 2008;58:71 96. Relative Survival*

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Non hormonal medical treatment of vasomotor symptoms

Non hormonal medical treatment of vasomotor symptoms Non hormonal medical treatment of vasomotor symptoms Caroline Antoine Menopause Clinic Department of Gynaecology and Obstetrics CHU Saint-Pierre Belgian Menopause Society Symposium November 14, 2015 No

More information

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay

More information

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI % 38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype

More information

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018 Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

Management of Perimenopausal symptoms

Management of Perimenopausal symptoms Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts

More information

WHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD

WHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD WHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD Conflicts? No financial conflicts of interest (Dr. Jones is a post menopausal female reproductive endocrinologist

More information

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus)

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus) HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric

More information

Menopause: diagnosis and management NICE guideline NG23. Published November 2015

Menopause: diagnosis and management NICE guideline NG23. Published November 2015 Menopause: diagnosis and management NICE guideline NG23 Published November 2015 1 Full title: Menopause : diagnosis and management Available at: http://www.nice.org.uk/guidance/ng23 Guideline published

More information

Hot flushes in breast cancer patients

Hot flushes in breast cancer patients Critical Reviews in Oncology/Hematology 57 (2006) 63 77 Hot flushes in breast cancer patients Constantijne H. Mom a, Ciska Buijs a, Pax H.B. Willemse a, Marian J.E. Mourits b, Elisabeth G.E. de Vries a,

More information

Management of Menopausal Symptoms

Management of Menopausal Symptoms Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of

More information

MENOPAUSAL HORMONE THERAPY 2016

MENOPAUSAL HORMONE THERAPY 2016 MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.

More information

The Latest Research: Hormonal Therapies

The Latest Research: Hormonal Therapies The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures

More information

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes

More information

Gary Elkins, PhD., ABPP

Gary Elkins, PhD., ABPP Gary Elkins, PhD., ABPP *What are Hot Flashes? *Hormone Replacement Therapy *Alternate Treatment Options *Clinical Hypnosis? *Methods *Preliminary Results *Conclusions & Future Directions *Over 66% of

More information

Citation for published version (APA): Buijs, C. (2008). Long-term side effects of adjuvant breast cancer treatment s.n.

Citation for published version (APA): Buijs, C. (2008). Long-term side effects of adjuvant breast cancer treatment s.n. University of Groningen Long-term side effects of adjuvant breast cancer treatment Buijs, Ciska IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite

More information

Menopausal Management: What Has Changed?

Menopausal Management: What Has Changed? Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning

More information

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help

More information

Menopause and Post Gynecological Reproductive Care

Menopause and Post Gynecological Reproductive Care Menopause and Post Gynecological Reproductive Care Nguyet-Cam Vu Lam, MD, FAAFP Associate Program Director St. Luke s Family Medicine Residency 1 Disclosure Dr. Nguyet-Cam Vu Lam has no conflict of interest,

More information

Gabapentin to treat hot flashes

Gabapentin to treat hot flashes P ford residence southampton, ny Gabapentin to treat hot flashes 6-10-2010 An extendedrelease version of the seizure and pain drug gabapentin may be one step closer to becoming the first approved nonhormonal

More information

Potential dangers of hormone replacement therapy in women at high risk

Potential dangers of hormone replacement therapy in women at high risk ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department

More information

Extended Hormonal Therapy

Extended Hormonal Therapy Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early

More information

ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA

ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)

More information

Menopause Symptoms and Management: After Breast Cancer

Menopause Symptoms and Management: After Breast Cancer Menopause Symptoms and Management: After Breast Cancer An Educational Webinar for Patients and their Caregivers Wen Shen, MD, MPH Division of Gynecologic Specialties July 27, 2018 1 Disclosure I have a

More information

Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration

Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed

More information

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate

More information

REFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10

REFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10 PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Follow-up Care of Breast Cancer Patients

Follow-up Care of Breast Cancer Patients Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 24 November 2018 Disclosures

More information

Menopause management NICE Implementation

Menopause management NICE Implementation Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not

More information

Hormone therapy in Breast Cancer patients with comorbidities

Hormone therapy in Breast Cancer patients with comorbidities Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal

More information

Breast Cancer. Dr. Andres Wiernik 2017

Breast Cancer. Dr. Andres Wiernik 2017 Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk

More information

Follow-up Care of Breast Cancer Patients

Follow-up Care of Breast Cancer Patients Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 19 April 2018 Disclosures

More information

Lessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1

Lessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1 Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant

More information

Lessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh

Lessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant

More information

SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer

SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical

More information

Trial: Take-Home Message: Executive Summary: Guidelines:

Trial: Take-Home Message: Executive Summary: Guidelines: Trial: Davies C, et al. "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial".

More information

Complementary Therapy. Hormonal Treatment and Alternatives in Breast Cancer Survivors

Complementary Therapy. Hormonal Treatment and Alternatives in Breast Cancer Survivors Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Complementary Therapy Hormonal Treatment and Alternatives in Breast Cancer Survivors Survivorship Complementary Therapy Hormonal

More information

Quality of life (QoL) in metastatic breast cancer patients with. maintenance paclitaxel plus gemcitabine (PG) chemotherapy:

Quality of life (QoL) in metastatic breast cancer patients with. maintenance paclitaxel plus gemcitabine (PG) chemotherapy: Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy

More information

Acne rosacea is a skin condition that causes facial flushing and can co-exist with menopausal flushing.

Acne rosacea is a skin condition that causes facial flushing and can co-exist with menopausal flushing. MANAGING HOT FLUSHES In Western societies, the most common menopause symptom is the hot flush. This typically begins as a feeling of heat in the chest or upper body which then spreads all over the body,

More information

Primary Care of the Breast Cancer Survivor. Case Presentation. Case Presentation (cont) Case Presentation (cont) Breast Cancer

Primary Care of the Breast Cancer Survivor. Case Presentation. Case Presentation (cont) Case Presentation (cont) Breast Cancer Primary Care of the Breast Cancer Survivor Janet P. Pregler, MD Professor of Clinical Medicine Director, Iris Cantor UCLA Women s Health Center Case Presentation B.C. is a 58 year-old African American

More information

Treatment of Vasomotor Symptoms in a Transgender Male After Hysterectomy. Isabel Casimiro, MD PhD Endocrinology Fellow

Treatment of Vasomotor Symptoms in a Transgender Male After Hysterectomy. Isabel Casimiro, MD PhD Endocrinology Fellow Treatment of Vasomotor Symptoms in a Transgender Male After Hysterectomy Isabel Casimiro, MD PhD Endocrinology Fellow Disclosure Information I have the following financial relationships to disclose: Consultant

More information

TRIAL SYNOPSIS. Title: National, phase III, multicentre, double-blind, placebo controlled, randomised trial. Trial Design:

TRIAL SYNOPSIS. Title: National, phase III, multicentre, double-blind, placebo controlled, randomised trial. Trial Design: TRIAL SYNOPSIS Title: A Phase III randomised study of FOlic Acid supplementation in the management of Menopausal symptoms in cancer survivors and healthy postmenopausal women (FOAM Trial) Trial Design:

More information

Survivorship in Cancer Care. Samantha Gray Medical Oncologist, SJRH April 20, 2018

Survivorship in Cancer Care. Samantha Gray Medical Oncologist, SJRH April 20, 2018 + Survivorship in Cancer Care Samantha Gray Medical Oncologist, SJRH April 20, 2018 + Disclaimers n Participated in Advisory Boards for Amgen, Astellas, Bayer, Janssen, Novartis, Pfizer, Sanofi n Have

More information

Applying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1

Applying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1 Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:

More information

Qamar J. Khan Bruce F. Kimler Pavan S. Reddy Priyanka Sharma Jennifer R. Klemp Carol J. Fabian

Qamar J. Khan Bruce F. Kimler Pavan S. Reddy Priyanka Sharma Jennifer R. Klemp Carol J. Fabian The VITAL trial Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole. Qamar J. Khan Bruce F. Kimler Pavan

More information

Medicines Management Group

Medicines Management Group SHARED CARE PROTOCOL for FULVESTRANT (FASLODEX ) INJECTION Scope Fulvestrant may be considered for shared care arrangements for the treatment of metastatic breast cancer for disease relapse. Unique Identifier

More information

Applying Best Evidence to Menopause Management

Applying Best Evidence to Menopause Management Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:

More information

TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer

TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive

More information

SERMS, Hormone Therapy and Calcitonin

SERMS, Hormone Therapy and Calcitonin SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings

More information

Dealing with menopausal symptoms in breast cancer patients

Dealing with menopausal symptoms in breast cancer patients Dealing with menopausal symptoms in breast cancer patients Christian Egarter Prof, MD Head: Dept. Gyn. Endocrinology & Reproductive Medicine Medical University of Vienna Disclosure Gideon Richter: Speaker

More information

Living with an Induced Menopause

Living with an Induced Menopause Living with an Induced Menopause Dr Jenifer Sassarini Clinical Lecturer Obstetrics and Gynaecology University of Glasgow 2 February 2017 70% of women in UK living with breast cancer have hot flushes 1/3

More information

Individual Study Table Referring to Part of the Dossier. Volume: Page:

Individual Study Table Referring to Part of the Dossier. Volume: Page: 1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators

More information

RALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer?

RALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer? Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA 16917 GUIDELINES FOR USE 1. Is the request for the prevention (risk reduction) of breast cancer? If yes, continue to #2. If no, approve by HICL

More information

Background History SSRIs for VMS

Background History SSRIs for VMS .pptx Non hormonal Pharmacologic Options: SSRIs/SNRIs/Gabapentin Susan D. Reed, MD, MPH Department of Obstetrics and Gynecology University of Washington, Seattle, WA Christopher Rasmussen, MD, InflaNATION

More information

Katarzyna Hojan 1, Marta Molińska-Glura 2, Piotr Milecki 3. ECRS Copenhagen 2012

Katarzyna Hojan 1, Marta Molińska-Glura 2, Piotr Milecki 3. ECRS Copenhagen 2012 The impact of physical activity on the association between changes in body build and quality of life in breast cancer women undergoing endocrine therapy Katarzyna Hojan 1, Marta Molińska-Glura 2, Piotr

More information

Disclosure Information Relationships Relevant to this Session

Disclosure Information Relationships Relevant to this Session Disclosure Information Relationships Relevant to this Session DeCensi, Andrea No relevant relationships to disclose. Please note, all disclosures are reported as submitted to ASCO, and are always available

More information

What to do about Sexual Dysfunction CAGPO Annual Meeting Recent Advances in Oncology Care Oct 20, 2012

What to do about Sexual Dysfunction CAGPO Annual Meeting Recent Advances in Oncology Care Oct 20, 2012 An Update on SURVIVORSHIP: What to do about Sexual Dysfunction 2012 CAGPO Annual Meeting Recent Advances in Oncology Care Oct 20, 2012 Elaine E. Jolly, OC, MD, FRCS(C) Professor of Obstetrics & Gynecology

More information

Flashpoint: Regulating Your Body s Temperature. Presented by: Shari M. Lawson, MD MBA Date Presented: November 1,

Flashpoint: Regulating Your Body s Temperature. Presented by: Shari M. Lawson, MD MBA Date Presented: November 1, Flashpoint: Regulating Your Body s Temperature Presented by: Shari M. Lawson, MD MBA Date Presented: November 1, 2014 1 Disclosures None 2 Objectives Today s discussion will cover How body temperature

More information

Non-hormonal interventions for hot flushes in women with a history of breast cancer (Review)

Non-hormonal interventions for hot flushes in women with a history of breast cancer (Review) Non-hormonal interventions for hot flushes in women with a history of breast cancer (Review) Rada G, Capurro D, Pantoja T, Corbalán J, Moreno G, Letelier LM, Vera C This is a reprint of a Cochrane review,

More information

Endocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology

Endocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer

More information

Women s Health: Take Home Messages

Women s Health: Take Home Messages Women s Health: Take Home Messages Caren Solomon, MD Associate Physician, BWH Associate Professor of Medicine, HMS Deputy Editor, NEJM No disclosures Contraception Contraceptive Effectiveness Rates of

More information

06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:

06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence: Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion

More information

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and

More information

Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance

Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine

More information

Long-Term Chinese Herbs Decoction Administration for Management of Hot Flashes Associated with Endocrine Therapy in Breast Cancer Patients

Long-Term Chinese Herbs Decoction Administration for Management of Hot Flashes Associated with Endocrine Therapy in Breast Cancer Patients 74 Chin J Cancer Res 23(1):74-78, 2011 www.springerlink.com Original Article Long-Term Chinese Herbs Decoction Administration for Management of Hot Flashes Associated with Endocrine Therapy in Breast Cancer

More information

TAS-108: A Novel Steroidal Anti-Estrogen for Treatment of Breast Cancer

TAS-108: A Novel Steroidal Anti-Estrogen for Treatment of Breast Cancer SRI Biosciences TAS-108: A Novel Steroidal Anti-Estrogen for Treatment of Breast Cancer Potential Indications Neo-adjuvant therapy for ER + primary breast cancers in premenopausal women Adjuvant therapy

More information

TITLE: Managing Menopausal Symptoms in Breast Cancer Survivors

TITLE: Managing Menopausal Symptoms in Breast Cancer Survivors AD GRANT NUMBER: DAMD17-94-J-4507 TITLE: Managing Menopausal Symptoms in Breast Cancer Survivors PRINCIPAL INVESTIGATOR: Patricia A. Ganz, M.D. CONTRACTING ORGANIZATION: University of California, Los Angeles

More information

Cancer Survivorship: What to Monitor and When to Intervene. Hyman B. Muss, MD 31 th Miami Breast Cancer Conference 2014

Cancer Survivorship: What to Monitor and When to Intervene. Hyman B. Muss, MD 31 th Miami Breast Cancer Conference 2014 Cancer Survivorship: What to Monitor and When to Intervene Hyman B. Muss, MD 31 th Miami Breast Cancer Conference 2014 Breast Cancer 2013 Incidence Mortality CA: A Cancer Journal for Clinicians pages 52-62,

More information

MENOPAUSAL SYMPTOMS ARE ASSOCIATED

MENOPAUSAL SYMPTOMS ARE ASSOCIATED MENOPAUSAL SYMPTOMS ARE ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN WOMEN LIVING WITH HIV Shema Tariq, Fiona Burns, Alexandra Rolland, Caroline Sabin, Lorraine Sherr, Richard Gilson (on behalf of the PRIME

More information

John J. Wolf, DO Family Medicine

John J. Wolf, DO Family Medicine John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize

More information

Oncotype DX testing in node-positive disease

Oncotype DX testing in node-positive disease Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype

More information

Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients

Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients

More information

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,

More information

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer Find Studies About Studies Submit Studies Resources About Site Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer The safety and scientific validity of this study is the responsibility

More information

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Chemo-endocrine prevention of breast cancer

Chemo-endocrine prevention of breast cancer Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;

More information

Interventions to Address Sexual Problems in People with Cancer

Interventions to Address Sexual Problems in People with Cancer A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Interventions to Address Sexual Problems in People with Cancer L. Barbera, C. Zwaal, D. Elterman, K. McPherson,

More information

Non medical alternative treatment of vasomotor symptomes

Non medical alternative treatment of vasomotor symptomes Non medical alternative treatment of vasomotor symptomes Dr Raffaella Votino BMS 14 nov. 2015 Plan : Why? When? Types? Conclusions! 2 Why? With increasing longevity,a women is expected to spend more than

More information

Manejo do câncer de mama RH+ na adjuvância: o que há de novo?

Manejo do câncer de mama RH+ na adjuvância: o que há de novo? II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,

More information

HRT & Menopause Where Do We Stand Now?

HRT & Menopause Where Do We Stand Now? HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study

More information

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases

More information

Aromatase Inhibitors & Osteoporosis

Aromatase Inhibitors & Osteoporosis Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health

More information

Eligibility, patient pathway & treatment. Amy Campbell Clinical Trial Coordinator

Eligibility, patient pathway & treatment. Amy Campbell Clinical Trial Coordinator Eligibility, patient pathway & treatment Amy Campbell Clinical Trial Coordinator Trial design Eligible patients consenting to OPTIMA 4500 patients 100 UK sites 4 years recruitment Randomisation 2250 2250

More information

Luminal early breast cancer: (neo-) adjuvant endocrine therapy

Luminal early breast cancer: (neo-) adjuvant endocrine therapy CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia

More information

Breast Cancer. Saima Saeed MD

Breast Cancer. Saima Saeed MD Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast

More information

Endocrine Steroids 2. Signal transduction 3. Prostaglandins

Endocrine Steroids 2. Signal transduction 3. Prostaglandins Endocrine - 2 1. Steroids 2. Signal transduction 3. Prostaglandins Estrogen Menopause (pause in the menes) ["change of life" at about 50] - lack of estrogen. (Some hysterectomy or ovarian cancer surgeries

More information

Breast Cancer Survivorship. Michelle Melisko MD Assistant Clinical Professor UCSF Breast Care Center

Breast Cancer Survivorship. Michelle Melisko MD Assistant Clinical Professor UCSF Breast Care Center Breast Cancer Survivorship Michelle Melisko MD Assistant Clinical Professor UCSF Breast Care Center Survivors Who are they? An estimated 210,000 women were diagnosed with breast cancer in the year 2007

More information

PRODUCT MONOGRAPH TEVA-LETROZOLE

PRODUCT MONOGRAPH TEVA-LETROZOLE PRODUCT MONOGRAPH Pr TEVA-LETROZOLE (letrozole tablets) 2.5 mg Teva Standard Non-steroidal aromatase inhibitor; inhibitor of estrogen biosynthesis; anti-tumour agent Teva Canada Limited Date of Revision:

More information

Pertuzumab for the adjuvant treatment of HER2-positive breast cancer

Pertuzumab for the adjuvant treatment of HER2-positive breast cancer Lead team presentation Pertuzumab for the adjuvant treatment of HER2-positive breast cancer 1 st Appraisal Committee meeting Background and clinical effectiveness Committee A Lead team: John McMurray,

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal myomectomy in leiomyoma management, 77 Abnormal uterine bleeding (AUB) described, 103 105 normal menstrual bleeding vs., 104

More information

The 22nd SEC (Oncology& hematology) meeting deliberated the proposals on and recommended the following:- volunteers.

The 22nd SEC (Oncology& hematology) meeting deliberated the proposals on and recommended the following:- volunteers. :- The 22nd SEC (Oncology& hematology) meeting deliberated the proposals on 14-01-2015 and recommended the following:- Agenda 1 peg-gcsf 4-270/Biocon Ltd./14 BD 2 Trastuzumab 4-237/Dr. Reddy/14-BD 3 GCSF

More information

Case Presentation. Learning Objectives. Case Presentation. Case Presentation

Case Presentation. Learning Objectives. Case Presentation. Case Presentation Learning Objectives To apply up to date information about the natural history of menopause to improve the care of individual women To counsel women about the risks and benefits of systemic hormone therapy

More information